Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants
A Randomized, Double-Blind, 3-arm, Parallel Group, Placebo- and Positive-controlled Study to Investigate the Effects of Setmelanotide on QTc Interval in Healthy Subjects
Sponsor: Rhythm Pharmaceuticals, Inc.
This PHASE4 trial investigates Healthy and is currently completed. Rhythm Pharmaceuticals, Inc. leads this study, which shows 7 recorded versions since 2021 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Jun 2024 — Jul 2024 [monthly]
Completed PHASE4
-
May 2023 — Jun 2024 [monthly]
Completed PHASE4
-
Jul 2022 — May 2023 [monthly]
Completed PHASE4
Status: Recruiting → Completed
▶ Show 2 earlier versions
-
Nov 2021 — Jul 2022 [monthly]
Recruiting PHASE4
-
Oct 2021 — Nov 2021 [monthly]
Recruiting PHASE4
First recorded
Aug 2021
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Rhythm Pharmaceuticals, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .